- $26.69bn
- $22.12bn
- $1.94bn
US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults
Refile: Ebola Bundibugyo vaccine candidates could enter Phase 1 trials as early as July
Brief: Moderna Organizational Changes To Prepare For Multiple Product Launches In 2027 And 2028
Moderna announces executive changes ahead of potential launches
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)
Commission appeal in COVID vaccine contract case should be dismissed, EU court adviser says
Focus: Cancer vaccines based on mRNA advance, despite US cuts (updated)
Focus: Cancer vaccines based on mRNA advance, despite US cuts
Health Rounds: Radiation-emitting implant improves outcomes after brain cancer surgery
Moderna and other groups get $60 million to develop Ebola vaccine (updated)
CEPI commits up to $50 million to develop Bundibugyo Ebola vaccine with Moderna
US FDA advisers vote in favor of recommending COVID vaccines target XFG variant
US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant (updated)
US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant
Moderna, Merck cancer combo cuts melanoma spread risk at five years
U.S. STOCKS ON THE MOVE-Moderna, Kontoor Brands, Ralph Lauren
U.S. STOCKS ON THE MOVE- Intuit, Deere, Advance Auto Parts
US FDA to hold expert committee meeting to review Moderna's flu vaccine (updated)
Moderna falls after US FDA to hold expert panel meeting to review flu vaccine